Lineage Cell Therapeutics Inc
TASE:LCTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Lineage Cell Therapeutics Inc
TASE:LCTX
|
US |
|
Lufax Holding Ltd
NYSE:LU
|
CN |
|
W
|
Waters Corp
XMUN:WAZ
|
US |
|
R
|
Realty Income Corp
F:RY6
|
US |
|
Austal Ltd
ASX:ASB
|
AU |
|
Celanese Corp
NYSE:CE
|
US |
|
H
|
Holcim AG
XMUN:HLBN
|
CH |
|
W
|
Western Digital Corp
DUS:WDC
|
US |
|
D
|
Duke Energy Corp
F:D2MN
|
US |
|
Crown Holdings Inc
NYSE:CCK
|
US |
|
A
|
Archrock Inc
F:54E
|
US |
|
C
|
Community Health Systems Inc
F:CG5
|
US |
|
P
|
PPG Industries Inc
XBER:PPQ
|
US |
|
G
|
Grupo Empresas Navieras SA
SGO:NAVIERA
|
CL |
|
A
|
AngloGold Ashanti Ltd
JSE:ANG
|
ZA |
|
S
|
Societe Generale SA
OTC:SCGLF
|
FR |
Wall St Price Targets
LCTX Price Targets Summary
Lineage Cell Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for LCTX is 1 613.6 ILS with a low forecast of 871.52 ILS and a high forecast of 2 718.1 ILS.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is LCTX's stock price target?
Price Target
1 613.6
ILS
According to Wall Street analysts, the average 1-year price target for LCTX is 1 613.6 ILS with a low forecast of 871.52 ILS and a high forecast of 2 718.1 ILS.
What is the Revenue forecast for Lineage Cell Therapeutics Inc?
Projected CAGR
74%
Over the last 14 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 8 years is 74%.
What is the Gross Profit forecast for Lineage Cell Therapeutics Inc?
Projected CAGR
74%
Over the last 14 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 8 years is 74%.
